Cavhanza is a drug owned by Flex Pharma Llc. It is protected by 4 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 30, 2041. Details of Cavhanza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11559485 | Orally Disintegrating Tablet Comprising Amorphous Solid Dispersion Of Nilotinib |
Apr, 2041
(14 years from now) | Active |
| US12029740 | Amorphous Nilotinib Microparticles And Uses Thereof |
Jan, 2041
(14 years from now) | Active |
| US12016861 | Amorphous Nilotinib Microparticles And Uses Thereof |
Jan, 2041
(14 years from now) | Active |
| US11389450 | Amorphous Nilotinib Microparticles And Uses Thereof |
Jan, 2041
(14 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Cavhanza is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Cavhanza's family patents as well as insights into
ongoing legal events
on those patents.
Cavhanza's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cavhanza's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 30, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cavhanza Generics:
There are no approved generic versions for Cavhanza as of now.
Alternative Brands for Cavhanza
There are several other brand drugs using the same active ingredient (Nilotinib) as Cavhanza. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Cavhanza
Cavhanza is a drug owned by Flex Pharma Llc. Cavhanza uses Nilotinib as an active ingredient. Cavhanza was launched by Flex in 2026.
Approval Date:
Cavhanza was approved by FDA for market use on 29 May, 2026.
Active Ingredient:
Cavhanza uses Nilotinib as the active ingredient. Check out other Drugs and Companies using Nilotinib ingredient
Dosage:
Cavhanza is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 60MG | TABLET, ORALLY DISINTEGRATING | Prescription | ORAL |
| 80MG | TABLET, ORALLY DISINTEGRATING | Prescription | ORAL |